Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05698212 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
A Phase 2 study of Endometriosis and Diagnosis, sponsored by Hera Biotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT05698212: Recruiting Phase 2 study of Endometriosis and Diagnosis, sponsored by Hera Biotech.
NCT05698212 is a Phase 2 study of Endometriosis and Diagnosis that is actively recruiting participants, run by Hera Biotech. The registered enrollment target is 75 participants, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05698212, a Phase 2 study of Endometriosis and Diagnosis, is actively recruiting participants, sponsored by Hera Biotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.
Primary Outcome
Endometriosis diagnosis
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MetriDx
Study Locations (3)
Texas
- Corpus Christi Women's Center - Corpus Christi
- University of Texas Physician's Women's Center--Memorial City - Houston
Michigan
- Valley OB-GYN Clinic, PC - Saginaw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 2 |
What NCT05698212 shows while recruiting
NCT05698212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Endometriosis appearing as the primary indexed condition, and to 1 intervention - of which MetriDx is the first listed.
NCT05698212 reports a single indexed study location in Texas, Michigan.
Frequently Asked Questions
What is clinical trial NCT05698212 about?
NCT05698212 is a clinical study titled "Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers". This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.
What is the current status of trial NCT05698212?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2022-09-14. Estimated completion is 2023-04-10.
What conditions does trial NCT05698212 study?
This clinical trial studies the following conditions: Endometriosis, Diagnosis.
What interventions are being tested in trial NCT05698212?
The interventions under investigation include: MetriDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05698212?
This trial is sponsored by Hera Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05698212 being conducted?
This trial has 3 study locations across Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05698212's enrollment target sits among peer trials
75 30th of 48 higher than 19 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
-
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
RECRUITING · Phase 2
-
Glycemic Regulation as Endometriosis Adjunct Treatment
RECRUITING · Phase 2
-
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
COMPLETED · Phase 2
-
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
COMPLETED · Phase 2
-
Endometriosis Trial: Study of NBI-56418 in Endometriosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI